Staphefekt: sustainable antibacterial therapy with endolysins Free Archived

Info

Please note that for mobiles we stream the presentation slides and audio of the speaker.

Info

This video has been archived as it is more than 2 years old. CPD is no longer available.

x Mobile version: slides + audio only
-15s 00:00 / 19:15 +15s
Minimise video

Mark Offerhaus and Bjorn Herpers give a talk on the development of Staphefekt - a new antibacterial technology for the treatment of infectious skin conditions (Staph. aureus). Staphefekt is completely independent of antibiotics and is based on the use of endolysins.

Bjorn Herpers talks through some patient cases, showing Staphefekt's success in the treatment of ezcema, rosacea, furunculosis and more. Micreos hope to set a new standard of treatment that will replace antibiotics, and have made Staphefekt free to use for research purposes.

This lecture was part of the 'Medical Innovations Summit 2015' at The Royal Society of Medicine in London.

Date of lecture: 18th April 2015

This video is available for iPad via Safari 

Length: 00:19:15

00:00:01 - Introduction
00:07:16 - Colonization Infection Continuum
00:15:36 - Sustainable Intervention
00:18:08 - Conclusion
00:00:01
00:00:21
00:01:07
00:01:24
00:01:35
00:01:46
00:02:50
00:03:03
00:05:18
00:05:50
00:05:56
00:06:05
00:06:29
00:06:36
00:06:41
00:06:47
00:07:01
00:07:23
00:07:50
00:08:10
00:08:31
00:08:37
00:09:21
00:09:46
00:09:53
00:09:56
00:10:02
00:10:17
00:10:25
00:10:47
00:11:42
00:12:16
00:12:19
00:12:31
00:13:07
00:13:29
00:14:15
00:14:30
00:15:00
00:15:20
00:15:56
00:16:05
00:16:29
00:16:56
00:17:23
00:18:15
19:25
Free Archived View
18:06

Dr Jamie Wilson, Founder and CEO of HomeTouch.

Free Archived View
19:15

Mark Offerhaus, CEO of Micreos and Bjorn Herpers, clinical microbiologist and an advisor to Micreos.

Free Archived View
16:58

Paul Varga, CEO and co-founder of Playbrush.

Free Archived View
23:04

Dr Paul Peter Tak, Head of Immunoinflammation at GlaxoSmithKline (GSK) and Professor at the Academic Medical Centre, University of Amsterdam.

Free Archived View
13:56

Kenneth Shinozuka, winner of the third annual $50,000 Scientific American Science in Action Award.

Free Archived View